Aperçu du dossier

Les parties

Brevets en cause

This case involved an exceptionally broad portfolio of **18 U.S. patents** asserted by Exeltis, spanning multiple patent families and filing generations, all protecting SLYND® (drospirenone).

• • US9603860B2 — Drospirenone formulations
• • US10179140B2 — Pharmaceutical compositions
• • US10603281B2 — Contraceptive kit configurations
• • US10849857B2 — Methods of administration
• • US10987364B1 — Synthetic progestogens
• • US11123299B2 — Drug formulations and uses
• • US11291632B2 — Extended release compositions
• • US11291633B2 — Contraceptive methods
• • US11351122B1 — Tablet compositions
• • US11413249B2 — Oral contraceptives
• • US11439598B2 — Drospirenone dosage forms
• • US11452695B2 — Regimens for contraception
• • US11478487B1 — Pharmaceutical kits
• • US11491113B1 — Methods of contraception
• • US11504334B2 — Drospirenone for continuous use
• • US11951213B2 — Pharmaceutical compositions
• • US12090231B2 — Dosing regimens
• • US12280151B2 — Packaging and administration

Le verdict et l'analyse juridique

Résultat

The case concluded via **stipulated dismissal with prejudice** pursuant to agreement between both parties. The dismissal covered all claims and all defenses in their entirety. Critically, the parties agreed to bear their own costs and attorneys’ fees — a mutual walk-away structure that neither confirms infringement nor establishes invalidity as a matter of public record. Specific financial terms, licensing arrangements, or ANDA-related agreements were not publicly disclosed.

Analyse des causes du verdict

The operative cause was an **infringement action** under the Hatch-Waxman Act, in which an ANDA filing by a generic manufacturer constitutes a statutory act of infringement upon which a brand-name patent holder may sue prior to product launch. This framework creates a structured 30-month stay of FDA approval — providing Exeltis with a powerful incentive to litigate even where the ultimate commercial risk is prospective rather than immediate.

The breadth of the asserted patent portfolio — 18 patents spanning formulation, composition, kits, and method claims across multiple patent families — is itself a litigation signal. Assembling such a portfolio maximizes claim surface area, complicates Glenmark’s invalidity and non-infringement analysis, and increases the cost and complexity of a contested defense.

Signification juridique

While this dismissal does not establish binding precedent on claim construction, validity, or infringement, it contributes to the observable pattern in pharmaceutical patent litigation where densely layered patent estates around blockbuster or differentiated products create substantial barriers to generic entry — barriers that frequently resolve in negotiated outcomes rather than adjudicated verdicts.

The case also reflects the continued strategic value of continuation patent practice: several of the 18 asserted patents share application lineages, suggesting an intentional prosecution strategy designed to extend and diversify claim coverage over time.